Sandoz Looks To Join EU Trastuzumab Party With CHMP Thumbs Up
Herwenda Biosimilar Referencing Herceptin In-Licensed From EirGenix In 2019
Sandoz looks to be in line for an EU-wide approval for its trastuzumab biosimilar during 2023, with the backing of the EMA’s Committee for Medicinal Products for Human Use.
